Literature DB >> 27111042

Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.

M E Dourthe1, N Ternès2, D Gajda2, A Paci3, C Dufour1, E Benhamou2, D Valteau-Couanet1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27111042     DOI： 10.1038/bmt.2016.109

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  13 in total

1.  The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.

Authors:  M Hassan; P Ljungman; O Ringdén; Z Hassan; G Oberg; C Nilsson; A Békassy; M Bielenstein; M Abdel-Rehim; S Georén; L Astner
Journal:  Bone Marrow Transplant       Date:  2000-05       Impact factor: 5.483

2.  Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients.

Authors:  J T Slattery; T F Kalhorn; G B McDonald; K Lambert; C D Buckner; W I Bensinger; C Anasetti; F R Appelbaum
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

3.  Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.

Authors:  N Cantoni; S Gerull; D Heim; J Halter; C Bucher; A Buser; D A Tsakiris; J Passweg; A Tichelli; M Stern; A Gratwohl
Journal:  Bone Marrow Transplant       Date:  2010-06-14       Impact factor: 5.483

4.  Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial.

Authors:  Ruth Ladenstein; Ulrike Pötschger; Marie Cécile Le Deley; Jeremy Whelan; Michael Paulussen; Odile Oberlin; Henk van den Berg; Uta Dirksen; Lars Hjorth; Jean Michon; Ian Lewis; Alan Craft; Heribert Jürgens
Journal:  J Clin Oncol       Date:  2010-06-14       Impact factor: 44.544

5.  Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution.

Authors:  O Hartmann; D Valteau-Couanet; G Vassal; V Lapierre; L Brugières; R Delgado; D Couanet; J Lumbroso; E Benhamou
Journal:  Bone Marrow Transplant       Date:  1999-04       Impact factor: 5.483

6.  Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.

Authors:  Odile Oberlin; Annie Rey; Anne Sophie Desfachelles; Thierry Philip; Dominique Plantaz; Claudine Schmitt; Emmanuel Plouvier; Odile Lejars; Hervé Rubie; Philippe Terrier; Jean Michon
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

7.  Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Authors:  K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds
Journal:  N Engl J Med       Date:  1999-10-14       Impact factor: 91.245

Review 8.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.

Authors:  Jason A Coppell; Paul G Richardson; Robert Soiffer; Paul L Martin; Nancy A Kernan; Allen Chen; Eva Guinan; Georgia Vogelsang; Amrita Krishnan; Sergio Giralt; Carolyn Revta; Nicole A Carreau; Massimo Iacobelli; Enric Carreras; Tapani Ruutu; Tiziano Barbui; Joseph H Antin; Dietger Niederwieser
Journal:  Biol Blood Marrow Transplant       Date:  2009-09-18       Impact factor: 5.742

9.  The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.

Authors:  B Sadeghi; M Jansson; Z Hassan; M Mints; H Hägglund; M Abedi-Valugerdi; M Hassan
Journal:  Bone Marrow Transplant       Date:  2008-01-28       Impact factor: 5.483

10.  The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.

Authors:  Z Hassan; E Hellström-Lindberg; S Alsadi; M Edgren; H Hägglund; M Hassan
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483
View more
  2 in total

1.  Token economy to improve adherence to activities of daily living.

Authors:  Victoria Hickey; Laura Flesch; Adam Lane; Ahna L H Pai; John Huber; Priscila Badia; Stella M Davies; Christopher E Dandoy
Journal:  Pediatr Blood Cancer       Date:  2018-07-26       Impact factor: 3.167

Review 2.  Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.

Authors:  Alan L Myers; Jitesh D Kawedia; Richard E Champlin; Mark A Kramer; Yago Nieto; Romi Ghose; Borje S Andersson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-08-17       Impact factor: 4.481
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.